{"nctId":"NCT01713530","briefTitle":"A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin","startDateStruct":{"date":"2013-02-21","type":"ACTUAL"},"conditions":["Diabetes","Diabetes Mellitus, Type 2"],"count":274,"armGroups":[{"label":"IDegAsp BID+/-OADs","type":"EXPERIMENTAL","interventionNames":["Drug: insulin degludec/insulin aspart"]},{"label":"IDeg OD plus IAsp +/-OADs","type":"EXPERIMENTAL","interventionNames":["Drug: insulin degludec","Drug: insulin aspart"]}],"interventions":[{"name":"insulin degludec/insulin aspart","otherNames":[]},{"name":"insulin degludec","otherNames":[]},{"name":"insulin aspart","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of type 2 Diabetes Mellitus at the discretion of the investigator for at least 26 weeks prior to screening (visit 1)\n* Treatment with basal insulin for at least 12 weeks prior to randomisation with or without metformin, sulphonylurea (SU)/glinide, DPP-4 inhibitors, alfa-glucosidase-inhibitors\n* HbA1c 7.0% - 10.0%\n* Body mass index (BMI) less than or equal to 40.0 kg/m\\^2\n\nExclusion Criteria:\n\n* Treatment with glucose-lowering agent(s) other than those stated in the inclusion criteria\n* Stroke; heart failure New York Heart Association (NYHA) class III or IV; myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or angioplasty\n* Chronic disorder or disease which might jeopardise safety or compliance\n* Malignant neoplasms\n* Recurrent severe hypoglycaemia","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in HbA1c (%)","description":"Change from baseline in HbA1c (%) after 26 weeks of treatment","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.23","spread":"0.13"},{"groupId":"OG001","value":"-1.42","spread":"0.12"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose (FPG)","description":"Change from baseline in FPG after 26 weeks of treatment","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.22","spread":"0.38"},{"groupId":"OG001","value":"-1.90","spread":"0.36"}]}]}]},{"type":"SECONDARY","title":"Number of Treatment Emergent Hypoglycaemic Episodes","description":"According to the Novo Nordisk definition for confirmed hypoglycaemic episodes (severe hypoglycaemia and/or a measured Plasma Glucose (PG) \\<3.1 mmol/L(56 mg/dL))","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"706","spread":null},{"groupId":"OG001","value":"841","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Treatment Emergent Hypoglycaemic Episodes","description":"According to the American Diabetes Association (ADA) definition following are the categories of hypoglycaemic episodes:\n\nSevere hypoglycaemia, Documented symptomatic hypoglycaemia, Asymptomatic hypoglycaemia, Probable symptomatic hypoglycaemia and Relative hypoglycaemia","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2894","spread":null},{"groupId":"OG001","value":"2685","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1818","spread":null},{"groupId":"OG001","value":"1843","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"930","spread":null},{"groupId":"OG001","value":"728","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91","spread":null},{"groupId":"OG001","value":"66","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Treatment Emergent Nocturnal (00:01-05:59 am) Confirmed Hypoglycaemic Episodes","description":"Nocturnal hypoglycaemic episodes are defined as occurring between 00:01 and 05:59 a.m.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75","spread":null},{"groupId":"OG001","value":"96","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Treatment Emergent Adverse Events (TEAE)","description":"A TEAE was defined as an event that has onset date on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"330","spread":null},{"groupId":"OG001","value":"298","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":136},"commonTop":["Nasopharyngitis","Diarrhoea","Headache","Influenza","Asthenia"]}}}